OasisLMS

Attend the Foundations of Obesity Care Course immediately preceding ObesityWeek 2024, where primary care physicians, academics, and inter-professional team members explore the complexities of effectively treating obesity. This continuing medical education event delves into the multifaceted nature of obesity, addressing its status as both a disease and a significant contributor to chronic conditions. Gain invaluable insights as we delve into weight bias recognition, weight history assessment, and identification of primary and secondary causes of obesity. Discover the key elements of assessing obesity-related complications such as NAFLD, PCOS, diabetes, cardiovascular diseases, and chronic kidney disease; and learn how to properly employ first-level anti-obesity medications. Explore metabolic-bariatric surgical options and establish long-term management expectations. Expand your clinical knowledge, connect with leading experts, and gain the confidence to effectively treat patients with overweight or obesity in this concise weekend course.

This course is a ticketed event at the ObesityWeek conference requiring separate payment. All in-person course registrants will also receive on-demand recordings of the course at no additional fee. This 2-day course confers up to 12 CME credits (credits are listed by day) that count toward ABIM MOC credits. This and all CME events produced by The Obesity Society count towards Group One credit when applying for the American Board of Obesity Medicine exam.

Beverages are served at this event. Meals are not included. Please have breakfast before you arrive. A 90-minute lunch break will happen at 12:15-1:45 pm to allow attendees to go out to lunch.

The Obesity Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Obesity Society designates this enduring material for a maximum of 12 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 12 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ACCME Activity ID 202790161

Date of Release: January 2, 2025
Date of Termination: December 31, 2027

No commercial support was received for this activity.

Agarwal, Monica, MD, MEHP, FACE: No Relevant Financial Relationships

Albert, Michael, MD: Advisor relationship with Elo Health (Medical Supplement). Consultant relationship with Gelesis (Medical Device) and Novo Nordisk (Pharmaceuticals). Stock Options relationship with Elo Health (Medical Supplement).

Bessesen, Daniel, MD, FTOS: Researcher relationship with Eli Lilly (Pharmaceuticals) and Novo Nordisk (Pharmaceuticals).

Butsch, Scott, MD, MSc, FTOS: Advisor relationship with Eli Lilly (Pharmaceuticals) and Novo Nordisk (Pharmaceuticals). Consultant relationship with Abbott (Medical Food).

Jastreboff, Ania, MD, PhD: Advisor relationship with Amgen (Pharmaceuticals), AstraZeneca (Pharmaceuticals, Boehringer Ingelheim (Pharmaceuticals), Biohaven (Pharmaceuticals), Eli Lilly (Pharmaceuticals), Novo Nordisk (Pharmaceuticals), Pfizer (Pharmaceuticals), Regeneron (Pharmaceuticals), Rhythm Pharmaceuticals (Pharmaceuticals), Scholar Rock (Pharmaceuticals), Structure Therapeutics (Pharmaceuticals), Terns (Pharmaceuticals), Weight Watchers (Medical Food), and Zealand Pharmaceuticals (Pharmaceuticals). Researcher relationship with Boehringer Ingelheim (Pharmaceuticals), Eli Lilly (Pharmaceuticals), Novo Nordisk (Pharmaceuticals), and Rhythm Pharmaceuticals (Pharmaceuticals).

Lofton, Holly, MD, DiplABOM: Advisor relationship with Medifast (Medical Food), Novo Nordisk (Pharmaceuticals), and Robard Corporation (Medical Food). Researcher relationship with Eli Lilly (Pharmaceuticals) and Novo Nordisk (Pharmaceuticals). Speaker relationship with Novo Nordisk (Pharmaceuticals).

Machineni, Sriram, MD: Advisor relationship with Eli Lilly (Pharmaceuticals). Consultant relationship with Novo Nordisk (Pharmaceuticals). Researcher relationship with Ricordati (Pharmaceuticals).

McCormack, Debbie: No relevant financial relationships

Newton, Robert, Jr., PhD: No relevant financial relationships

Purnell, Jonathan, MD, FTOS, DiplABOM: Advisor relationship with Boehringer Ingelheim (Pharmaceuticals), Luciole (Pharmaceuticals), Novo Nordisk (Pharmaceuticals), and Regeneron Pharmaceuticals (Pharmaceuticals).

Shah, Meera, MD: No Relevant Financial Relationships

Velazquez, Amanda, MD, DiplABOM: Advisor relationship with Weight Watchers (Medical Food). Consultant relationship with Eli Lilly (Pharmaceuticals) and Novo Nordisk (Pharmaceuticals).

Agarwal, Monica, MD, MEHP, FACE: No Relevant Financial Relationships

Purnell, Jonathan, MD, FTOS, DiplABOM: Advisor relationship with Boehringer Ingelheim (Pharmaceuticals), Luciole (Pharmaceuticals), Novo Nordisk (Pharmaceuticals), and Regeneron Pharmaceuticals (Pharmaceuticals).

No members of the TOS CME Oversight Committee, charged with the resolution of all relevant conflicts of interest, had any relevant financial relationships while serving on the committee.

1. Schwartz MW, et al. Obesity Pathogenesis: An Endocrine Society Scientific Statement. Endocr Rev. 2017;38(4):267-

296.
2. Bray GA, et al. The Science of Obesity Management: An Endocrine Society Scientific Statement. Endocr Rev. 2018;39(2):79-132.
3. Rubino F, et al. Joint international consensus statement for ending stigma of obesity. Nat Med. 2020;26(4):485-497.
4. TOS Guidelines (2013) for managing overweight and obesity in adults. https://doi.org/10.1002/oby.20818.

5. Anderson J, et al. Overweight and Obesity Management for Primary Care Clinicians: Executive Summary. Clinical Diabetes. 2022. 41, 85-89.
6. Caterson ID, et al. Gaps to bridge: Misalignment between perception, reality and actions in obesity. Diabetes, obesity & metabolism. 2019. 21, 1914-1924.
7. Tucker S, et al. The Most Undertreated Chronic Disease: Addressing Obesity in Primary Care Settings. Curr Obes Rep.

2021. 10, 396-408.